The tie up allows the companies to evaluate the effectiveness of sclerostin antibody on the loss of bone linked with space flight in mice.
The sclerostin antibody inhibits the action of ‘sclerostin’, a protein that is a key negative regulator of bone formation, bone mass, and bone strength.
In the study, the companies will assess different aspects of the structure, composition, strength, and cell and molecular nature of the bones from the flight and ground-based control mice.
Amgen scientific executive director Chris Paszty said this proof of principle study will enhance their understanding of the science behind the sclerostin antibody and arm them with important research to support potential future therapeutic applications in both astronauts and patients suffering from bone loss.